The Laryngoscope · 2025
Acid Suppression in Mild-Moderate Laryngomalacia Without GERD: A Randomized Controlled Trial.
СтатьяРандомизированное исследованиеПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shaffer Amber D, Balogun Zainab, Tobey Allison B J, Maguire Raymond C, Simons Jeffrey P, Dohar Joseph E, Mccoy Jennifer L, Rushchak Marina V, Padia Reema
Аннотация
OBJECTIVE: To determine the efficacy of acid suppression therapy (AST) for the treatment of gastroesophageal reflux (GER) and airway symptoms in infants with mild to moderate laryngomalacia.
METHODS: From 2020 to 2023, infants ≤ 6 months old with laryngomalacia at a tertiary children's hospital were randomized to famotidine and feeding modifications (AST) or feeding modifications alone (no-AST). Laryngomalacia Airway Symptom Score (LASS) and Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) were completed by guardians. Of 343 patients approached, 257 were excluded due to severe laryngomalacia on LASS, severe GER (I-GERQ-R ≥ 16), prior AST, no laryngomalacia on laryngoscopy, recommendation for supraglottoplasty, and/or other airway anomalies. Twenty-one declined participation. LASS and I-GERQ-R were again completed 1-6 months following enrollment.
RESULTS: Sixty-five patients enrolled; 40/65 (62%) followed up at a mean of 3.1 months (SD 1.4 months). Of these 40, 10 (25%) had mild and 30 (75%) had moderate laryngomalacia. Median I-GERQ-R was 11 (range 5-15) at the initial appointment and 7.5 (range 0-26) at follow-up (p = 0.002). Laryngomalacia resolved in 13/40 (33%) at follow-up based on LASS (p < 0.001). Patients randomized to AST (n = 20) and no-AST (n = 20) had comparable improvement on LASS (p = 0.3) and I-GERQ-R (p = 0.8). Additionally, the severity of laryngomalacia at initial consult did not have a significant impact on LASS (p = 0.3) or I-GERQ-R (p = 0.8) improvement. LASS (ρ = 0.423, p = 0.007) but not I-GERQ-R (ρ = 0.122, p = 0.5) improved more with longer time from consult to follow-up.
CONCLUSION: This small randomized controlled trial was unable to demonstrate additional benefit from AST compared to feeding modifications alone based on airway and reflux symptoms.
TRIAL REGISTRATION: https://clinicaltrials.gov/study/NCT04614974.
METHODS: From 2020 to 2023, infants ≤ 6 months old with laryngomalacia at a tertiary children's hospital were randomized to famotidine and feeding modifications (AST) or feeding modifications alone (no-AST). Laryngomalacia Airway Symptom Score (LASS) and Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) were completed by guardians. Of 343 patients approached, 257 were excluded due to severe laryngomalacia on LASS, severe GER (I-GERQ-R ≥ 16), prior AST, no laryngomalacia on laryngoscopy, recommendation for supraglottoplasty, and/or other airway anomalies. Twenty-one declined participation. LASS and I-GERQ-R were again completed 1-6 months following enrollment.
RESULTS: Sixty-five patients enrolled; 40/65 (62%) followed up at a mean of 3.1 months (SD 1.4 months). Of these 40, 10 (25%) had mild and 30 (75%) had moderate laryngomalacia. Median I-GERQ-R was 11 (range 5-15) at the initial appointment and 7.5 (range 0-26) at follow-up (p = 0.002). Laryngomalacia resolved in 13/40 (33%) at follow-up based on LASS (p < 0.001). Patients randomized to AST (n = 20) and no-AST (n = 20) had comparable improvement on LASS (p = 0.3) and I-GERQ-R (p = 0.8). Additionally, the severity of laryngomalacia at initial consult did not have a significant impact on LASS (p = 0.3) or I-GERQ-R (p = 0.8) improvement. LASS (ρ = 0.423, p = 0.007) but not I-GERQ-R (ρ = 0.122, p = 0.5) improved more with longer time from consult to follow-up.
CONCLUSION: This small randomized controlled trial was unable to demonstrate additional benefit from AST compared to feeding modifications alone based on airway and reflux symptoms.
TRIAL REGISTRATION: https://clinicaltrials.gov/study/NCT04614974.